KEVIN CROMER: Open Payments
NPI 1184256174 · SPARTANBURG, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$590 in 21 payments from 7 companies in 2025. Trend: 2023 $402 · 2024 $597 · 2025 $590
Food & beverage: $590
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $135 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $120 |
| Axsome Therapeutics, Inc. | 1 | $115 |
| Otsuka America Pharmaceutical, Inc. | 4 | $85 |
| ABBVIE INC. | 3 | $78 |
| E.R. Squibb & Sons, L.L.C. | 2 | $40 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
Products named: TRINTELLIX, CAPLYTA, Auvelity, REXULTI, VRAYLAR, COBENFY, HETLIOZ.
Industry payments across SC — which companies pay providers there.
